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T

he initial Guide to the Primary Prevention of Cardiovascular Diseases was published in 1997 as an aid to
healthcare professionals and their patients without established
coronary artery disease or other atherosclerotic diseases.1 It
was intended to complement the American Heart Association
(AHA)/American College of Cardiology (ACC) Guidelines
for Preventing Heart Attack and Death in Patients with
Atherosclerotic Cardiovascular Disease (updated2) and to
provide the healthcare professional with a comprehensive
approach to patients across a wide spectrum of risk. The
imperative to prevent the first episode of coronary disease or
stroke or the development of aortic aneurysm and peripheral
arterial disease remains as strong as ever because of the
still-high rate of first events that are fatal or disabling or
require expensive intensive medical care. The evidence that
most cardiovascular disease is preventable continues to grow.
Results of long-term prospective studies consistently identify
persons with low levels of risk factors as having lifelong low
levels of heart disease and stroke.3,4 Moreover, these low
levels of risk factors are related to healthy lifestyles. Data
from the Nurses Health Study,5 for example, suggest that in
women, maintaining a desirable body weight, eating a healthy
diet, exercising regularly, not smoking, and consuming a
moderate amount of alcohol could account for an 84%
reduction in risk, yet only 3% of the women studied were in
that category. Clearly, the majority of the causes of cardiovascular disease are known and modifiable.
This 2002 update of the Guide acknowledges a number of
advances in the field of primary prevention since 1997.
Research continues to refine the recommendations on detec-

tion and management of established risk factors, including
evidence against the safety and efficacy of interventions once
thought promising (eg, antioxidant vitamins).6 This, in turn,
has stimulated a large number of additional guidelines for
specific demographic groups (eg, women), on individual risk
factors (eg, diabetes, smoking), and for the primary prevention of stroke. In all of these guidelines, there is an increasing
emphasis on further stratifying patients by level of risk and
matching the intensity of interventions to the hazard for
cardiovascular disease events.7
Therefore, this 2002 update of the Primary Prevention
Guide serves to integrate other guidelines and consensus
statements developed since the initial Guide’s approval. This
Guide might be viewed as the entry point to the more specific
and detailed recommendations and the rationale behind them.
The recommendations, as presented in the accompanying
tables, are therefore consistent with the following recommendations: Agency for Healthcare Policy and Research Guidelines on Treating Tobacco Use and Dependence8; the Sixth
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure
(JNC VI)9; the AHA Dietary Guidelines, Revision 200010; the
AHA Statement on Alcohol and Heart Disease11; the Third
Report of the National Cholesterol Education Program Expert
Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults12; American Heart Association Scientific Statements and Advisories on Physical Activity13,14 and
the American College of Sports Medicine Guidelines15; the
Clinical Guidelines for the Identification, Evaluation, and
Treatment of Overweight and Obesity in Adults from the
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Guide to Primary Prevention of Cardiovascular Disease and Stroke: Risk Assessment

Risk Assessment

Recommendations

Risk factor screening
Goal: Adults should know the levels and significance of
risk factors as routinely assessed by their primary care
provider.

Risk factor assessment in adults should begin at age 20 y. Family history of CHD should be
regularly updated. Smoking status, diet, alcohol intake, and physical activity should be assessed at
every routine evaluation. Blood pressure, body mass index, waist circumference, and pulse (to
screen for atrial fibrillation) should be recorded at each visit (at least every 2 y). Fasting serum
lipoprotein profile (or total and HDL cholesterol if fasting is unavailable) and fasting blood glucose
should be measured according to patient’s risk for hyperlipidemia and diabetes, respectively (at
least every 5 y; if risk factors are present, every 2 y).

Global risk estimation
All adults ⱖ40 y of age should know their absolute risk
of developing CHD. Goal: As low risk as possible.

Every 5 y (or more frequently if risk factors change), adults, especially those ⱖ40 y of age or
those with ⱖ2 risk factors, should have their 10-y risk of CHD assessed with a multiple risk
score. Risk factors used in global risk assessment include age, sex, smoking status, systolic (and
sometimes diastolic) blood pressure, total (and sometimes LDL) cholesterol, HDL cholesterol,12,28
and in some risk scores, diabetes.29,30 Persons with diabetes or 10-y risk ⬎20% can be
considered at a level of risk similar to a patient with established cardiovascular disease (CHD risk
equivalent). Equations for calculation of 10-y stroke risk are also available.

CHD indicates coronary heart disease.

National Heart, Lung, and Blood Institute Expert Panel16 and
an accompanying statement from the AHA Nutrition Committee17; the American Diabetes Association Standards of
Medical Care for Patients with Diabetes18,19 and the AHA
Statement on Diabetes and Cardiovascular Disease20; the
AHA Guidelines on the Primary Prevention of Stroke21; AHA
Guidelines for Prevention of Cardiovascular Disease in
Women22; ACC/AHA/European Society of Cardiology
(ESC) Guidelines for the Management of Patients With Atrial
Fibrillation23; the AHA Scientific Statement on Hormone
Replacement Therapy and Cardiovascular Disease24; and the
US Preventive Services Task Force evidence for use of
aspirin in primary prevention.25 The aspirin guidelines recommended here agree with the Task Force Report in the use
of aspirin in persons at high coronary and stroke risk but use
a ⱖ10% risk per 10 years rather than ⬎6% risk over 10 years.
This improves the likelihood of a positive balance of coronary risk reduction over bleeding and hemorrhagic stroke
caused by aspirin.26,27
Although this Guide largely applies to adults, it does
identify high-risk patients for whom screening and intervention in first-degree relatives (including children) would be an
important aspect of primary prevention. However, this Guide
will not provide specific recommendations for the reduction
of cardiovascular risk in children and adolescents. This
important issue will be the subject of a separate guide.
However, a family-centered approach to primary prevention
should be emphasized, inasmuch as it recognizes both the
genetic and behavioral causes of the well-established familial
aggregation of heart disease and stroke.
This Guide is intended to assist primary care providers in
their assessment, management, and follow-up of patients who
may be at risk for but who have not yet manifested cardiovascular disease. The continuing message is that adoption of
healthy life habits remains the cornerstone of primary prevention, including the avoidance of tobacco (including secondhand smoke), healthy dietary patterns, weight control, and
regular, appropriate exercise. An important role of healthcare
providers is to support and reinforce these public health
recommendations for all patients.
Table 1 is presented to guide the identification and assess-

ment of modifiable risk. The assessment of absolute cardiac
risk is increasingly advocated by international organizations
and by individual risk factor guidelines in the United
States.12,25,28 The Framingham database has been widely
used, though we acknowledge that the multiple risk score
may not apply equally to all sex, race, and ethnic groups.29,30
The use of more sophisticated technologies than a risk factor
inventory and global risk score has been addressed,31 and we
conclude that most screening tests for occult atherosclerosis
remain in the research arena, with the exception of the
ankle-brachial blood pressure index. Similarly, those recommended interventions involving “nutriceutical” and pharmaceutical interventions in Table 2 have support from randomized clinical trials establishing their efficacy and safety. More
controversial interventions, such as very low-fat diets,32
dietary supplements,6,33 and potentially cardioprotective
drugs other than aspirin require additional investigation in
well-designed clinical trials in persons without established
cardiovascular disease.
The gap between which evidence-based interventions are
recommended and what is actualized is large.34,35 Guidelines,
even when based on the best available evidence from randomized, controlled trials, cannot be successfully implemented without acceptance by the entire healthcare team,
including physicians, nurses, nutritionists, and other healthcare professionals. A physician-patient partnership must be
forged, on the physician’s part by assessing and communicating risk and by codeveloping with the patient a plan of
preventive action. New tools for providers are available to
foster this partnership, such as the AHA’s Get With the
Guidelines.36 Information for the public on cardiovascular
and stroke risk factors is available on the AHA web site.37
The challenge for healthcare professionals is to engage
greater numbers of patients, at an earlier stage of their
disease, in comprehensive cardiovascular risk reduction with
the use of interventions that are designed to circumvent or
alleviate barriers to participation and adherence, so that many
more individuals may realize the benefits that primary prevention can provide. The healthcare professional should
create an environment supportive of risk factor change,
including long-term reinforcement of adherence to lifestyle
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Guide to Primary Prevention of Cardiovascular Disease and Stroke: Risk Intervention

Risk Intervention and Goals

Recommendations

Smoking
Goal: Complete cessation. No exposure to
environmental tobacco smoke.

Ask about tobacco use status at every visit. In a clear, strong, and personalized manner, advise every tobacco user
to quit. Assess the tobacco user’s willingness to quit. Assist by counseling and developing a plan for quitting.
Arrange follow-up, referral to special programs, or pharmacotherapy. Urge avoidance of exposure to secondhand
smoke at work or home.

BP control
Goal: ⬍140/90 mm Hg; ⬍130/85 mm Hg if
renal insufficiency or heart failure is present;
or ⬍130/80 mm Hg if diabetes is present.

Promote healthy lifestyle modification. Advocate weight reduction; reduction of sodium intake; consumption of fruits,
vegetables, and low-fat dairy products; moderation of alcohol intake; and physical activity in persons with BP of
ⱖ130 mm Hg systolic or 80 mm Hg diastolic. For persons with renal insufficiency or heart failure, initiate drug
therapy if BP is ⱖ130 mm Hg systolic or 85 mm Hg diastolic (ⱖ80 mm Hg diastolic for patients with diabetes).
Initiate drug therapy for those with BP ⱖ140/90 mm Hg if 6 to 12 months of lifestyle modification is not effective,
depending on the number of risk factors present. Add BP medications, individualized to other patient requirements
and characteristics (eg, age, race, need for drugs with specific benefits).

Dietary intake
Goal: An overall healthy eating pattern.

Advocate consumption of a variety of fruits, vegetables, grains, low-fat or nonfat dairy products, fish, legumes,
poultry, and lean meats. Match energy intake with energy needs and make appropriate changes to achieve weight
loss when indicated. Modify food choices to reduce saturated fats (⬍10% of calories), cholesterol (⬍300 mg/d), and
trans-fatty acids by substituting grains and unsaturated fatty acids from fish, vegetables, legumes, and nuts. Limit
salt intake to ⬍6 g/d. Limit alcohol intake (ⱕ2 drinks/d in men, ⱕ1 drink/d in women) among those who drink.

Aspirin
Goal: Low-dose aspirin in persons at higher
CHD risk (especially those with 10-y risk of
CHD ⱖ10%).

Do not recommend for patients with aspirin intolerance. Low-dose aspirin increases risk for gastrointestinal bleeding
and hemorrhagic stroke. Do not use in persons at increased risk for these diseases. Benefits of cardiovascular risk
reduction outweigh these risks in most patients at higher coronary risk.25–27 Doses of 75–160 mg/d are as effective
as higher doses. Therefore, consider 75–160 mg aspirin per day for persons at higher risk (especially those with
10-y risk of CHD of ⱖ10%).

Blood lipid management
Primary goal: LDL-C ⬍160 mg/dL if ⱕ1 risk
factor is present; LDL-C ⬍130 mg/dL if ⱖ2
risk factors are present and 10-y CHD risk is
⬍20%; or LDL-C ⬍100 mg/dL if ⱖ2 risk
factors are present and 10-y CHD risk is
ⱖ20% or if patient has diabetes.
Secondary goals (if LDL-C is at goal range): If
triglycerides are ⬎200 mg/dL, then use
non-HDL-C as a secondary goal: non-HDL-C
⬍190 mg/dL for ⱕ1 risk factor; non-HDL-C
⬍160 mg/dL for ⱖ2 risk factors and 10-y
CHD risk ⱕ20%; non-HDL-C ⬍130 mg/dL for
diabetics or for ⱖ2 risk factors and 10-y CHD
risk ⬎20%.
Other targets for therapy: triglycerides ⬎150
mg/dL; HDL-C ⬍40 mg/dL in men and ⬍50
mg/dL in women.

If LDL-C is above goal range, initiate additional therapeutic lifestyle changes consisting of dietary modifications to
lower LDL-C: ⬍7% of calories from saturated fat, cholesterol ⬍200 mg/d, and, if further LDL-C lowering is required,
dietary options (plant stanols/sterols not to exceed 2 g/d and/or increased viscous [soluble] fiber [10–25 g/d]), and
additional emphasis on weight reduction and physical activity. If LDL-C is above goal range, rule out secondary
causes (liver function test, thyroid-stimulating hormone level, urinalysis). After 12 weeks of therapeutic lifestyle
change, consider LDL-lowering drug therapy if: ⱖ2 risk factors are present, 10-y risk is ⬎10%, and LDL-C is ⱖ130
mg/dL; ⱖ2 risk factors are present, 10-y risk is ⬍10%, and LDL-C is ⱖ160 mg/dL; or ⱕ1 risk factor is present
and LDL-C is ⱖ190 mg/dL. Start drugs and advance dose to bring LDL-C to goal range, usually a statin but also
consider bile acid–binding resin or niacin. If LDL-C goal not achieved, consider combination therapy (statin⫹resin,
statin⫹niacin). After LDL-C goal has been reached, consider triglyceride level: If 150–199 mg/dL, treat with
therapeutic lifestyle changes. If 200–499 mg/dL, treat elevated non-HDL-C with therapeutic lifestyle changes and, if
necessary, consider higher doses of statin or adding niacin or fibrate. If ⬎500 mg/dL, treat with fibrate or niacin to
reduce risk of pancreatitis. If HDL-C is ⬍40 mg/dL in men and ⬍50 mg/dL in women, initiate or intensify
therapeutic lifestyle changes. For higher-risk patients, consider drugs that raise HDL-C (eg, niacin, fibrates, statins).

Physical activity
Goal: At least 30 min of moderate-intensity
physical activity on most (and preferably all)
days of the week.

If cardiovascular, respiratory, metabolic, orthopedic, or neurological disorders are suspected, or if patient is
middle-aged or older and is sedentary, consult physician before initiating vigorous exercise program.
Moderate-intensity activities (40% to 60% of maximum capacity) are equivalent to a brisk walk (15–20 min per
mile). Additional benefits are gained from vigorous-intensity activity (⬎60% of maximum capacity) for 20–40 min on
3–5 d/wk. Recommend resistance training with 8–10 different exercises, 1–2 sets per exercise, and 10–15
repetitions at moderate intensity ⱖ2 d/wk. Flexibility training and an increase in daily lifestyle activities should
complement this regimen.

Weight management
Goal: Achieve and maintain desirable weight
(body mass index 18.5–24.9 kg/m2). When
body mass index is ⱖ25 kg/m2, waist
circumference at iliac crest level ⱕ40 inches
in men, ⱕ35 inches in women.

Initiate weight-management program through caloric restriction and increased caloric expenditure as appropriate. For
overweight/obese persons, reduce body weight by 10% in first year of therapy.

Diabetes management
Goals: Normal fasting plasma glucose (⬍110
mg/dL) and near normal HbA1c (⬍7%).

Initiate appropriate hypoglycemic therapy to achieve near-normal fasting plasma glucose or as indicated by
near-normal HbA1c. First step is diet and exercise. Second-step therapy is usually oral hypoglycemic drugs:
sulfonylureas and/or metformin with ancillary use of acarbose and thiazolidinediones. Third-step therapy is insulin.
Treat other risk factors more aggressively (eg, change BP goal to ⬍130/80 mm Hg and LDL-C goal to ⬍100
mg/dL).

Chronic atrial fibrillation
Goals: Normal sinus rhythm or, if chronic atrial
fibrillation is present, anticoagulation with INR
2.0–3.0 (target 2.5).

Irregular pulse should be verified by an electrocardiogram. Conversion of appropriate individuals to normal sinus
rhythm. For patients in chronic or intermittent atrial fibrillation, use warfarin anticoagulants to INR 2.0–3.0 (target
2.5). Aspirin (325 mg/d) can be used as an alternative in those with certain contraindications to oral anticoagulation.
Patients ⬍65 y of age without high risk may be treated with aspirin.

BP indicates blood pressure; CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; and INR,
international normalized ratio.
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and drug interventions. Practice-based systems for risk factor
monitoring, reminders, and support services need to be
established, reimbursed, and otherwise supported by managed care organizations and third-party payers. Primary
prevention, by its very nature, requires a lifetime of interactions that virtually define successful provider-patient
relationships.
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